Evidence Trace, complete trial record
In plain terms
In plain terms: Molecular Hydrogen Water shows early signals in human research but the evidence is limited -- small trials, surrogate endpoints, or not yet independently replicated. It is an emerging area, not yet a proven one.
Molecular Hydrogen Water
C
Limited: small, mixed or unreplicated trials
The endpoint this grade is based on: Surrogate biomarker endpoint
The evidence as the record states it
Ye et al. (Diabetol Metab Syndr, 2026; PMID 41888952): 13 randomized trials, 757 adults with overweight or obesity; total cholesterol 6.7 mg/dL and LDL 3.2 mg/dL lower than control, HDL slightly lower, triglycerides unchanged, effects the authors describe as below thresholds meaningful for cardiovascular risk. Jamialahmadi et al. (Int J Endocrinol Metab, 2024; PMID 39839806): 8 trials, 357 patients with metabolic disorders; only triglycerides fell, with confidence intervals for total and LDL cholesterol crossing zero. Todorovic et al. (Pharmaceuticals, 2023; PMID 37259294): 7 trials; small to moderate reductions in total cholesterol, LDL and triglycerides, from the Novi Sad group that runs several of the pooled trials. LeBaron et al. (Diabetes Metab Syndr Obes, 2020; PMID 32273740): 60 adults with metabolic syndrome, 24 weeks of high-concentration hydrogen water; cholesterol, glucose and HbA1c lower than placebo; part-funded by the maker of the tablets tested, with the lead author reporting consultancy and speaking fees from commercial entities regarding molecular hydrogen, stated beside the letter. Zanini et al. (Experimental Gerontology, 2021; PMID 34601077): 40-person pilot in adults aged 70 and over, 6 months; telomere length, a DNA methylation marker, brain metabolites and one physical test changed, lipid and metabolic outcomes did not, so it does not support the graded endpoint. Gaboreau et al. (J Clin Med, 2024; PMID 39124575), Hydro-COVID: phase 3, triple-blind, 675 primary care outpatients with mild to moderate COVID-19; hydrogen-rich water twice daily for 21 days did not reduce clinical worsening at day 14 (46.1 against 43.5 percent), graded D on Route 2 as a separate use. Grade C: small, inconsistent, clinically trivial surrogate changes. Inhaled molecular hydrogen is a separate intervention, graded separately.
PMID 34601077 PMID 41888952 PMID 39839806 PMID 37259294 PMID 32273740 PMID 39124575
Evidence by specific use
Total and LDL cholesterol in adults with overweight, obesity or metabolic disorders
Grade C
Mixed. Ye et al. (2026; PMID 41888952) pool 13 trials: total cholesterol about 7 mg/dL and LDL about 3 mg/dL lower, below the thresholds the authors consider meaningful. Jamialahmadi et al. (2024; PMID 39839806) pool 8 trials and find only triglycerides changed. Todorovic et al. (2023; PMID 37259294) pool 7 and find small to moderate reductions in all three, from a group that ran several of the trials. The key 24-week positive trial (LeBaron et al., 2020; PMID 32273740) was part-funded by the tablet maker, stated beside the letter. Small, inconsistent surrogate changes: C.
PMID 41888952 PMID 39839806 PMID 37259294 PMID 32273740
Clinical worsening in outpatients with mild to moderate COVID-19
Grade D
Gaboreau et al. (J Clin Med, 2024; PMID 39124575), Hydro-COVID: a phase 3, triple-blind, placebo-controlled multicenter trial in primary care. Hydrogen-rich water twice daily for 21 days did not reduce clinical worsening at day 14 (46.1 against 43.5 percent, hazard ratio 1.09). The largest hydrogen water trial on record, tested on its primary endpoint without benefit: D on Route 2.
PMID 39124575
Why Grade C and not Grade B
Grade C reflects early or limited human evidence -- small trials, surrogate endpoints, or preliminary findings not yet independently replicated. The evidence points in a promising direction but does not yet meet the standard for Grade B. A single well-powered, independently replicated trial with a meaningful endpoint would move this to Grade B or higher.
What this grade covers and what it does not
Grade C on blood lipids in adults with metabolic disorders. Three meta-analyses pool small randomized trials and disagree: the largest (Ye et al., 2026; PMID 41888952, 13 trials) finds total and LDL cholesterol lower by amounts its authors call below clinically meaningful thresholds, a second (Jamialahmadi et al., 2024; PMID 39839806) finds only triglycerides changed, and a third from a group that runs many of the trials (Todorovic et al., 2023; PMID 37259294) finds small to moderate reductions. The record's original citation, a 40-person pilot in adults aged 70 and over (Zanini et al., 2021; PMID 34601077), found no lipid or metabolic difference. The key positive 24-week trial was part-funded by the tablet maker (LeBaron et al., 2020; PMID 32273740). Small, inconsistent, clinically trivial surrogate changes are C. A phase 3 trial of 675 outpatients with COVID-19 found no reduction in clinical worsening (Gaboreau et al., 2024; PMID 39124575), graded D on Route 2 as a separate use. WHAT THIS GRADE DOES NOT COVER: inhaled hydrogen, graded separately; any clinical outcome; telomere length or other aging markers, measured in one pilot without replication; and hydrogen concentration at the point of use, which most commercial products do not verify.
What would move this grade
A well-powered randomized trial with an objective, clinically meaningful primary endpoint and at least one independent replication would support Grade B or higher.
How to track whether this is working
HsCRP and 8-isoprostane at baseline and 8 weeks for oxidative stress applications. Fasting glucose at baseline and 12 weeks for metabolic applications. Hydrogen concentration in solution must be verified at point of use: most commercial H2 water products degas rapidly and deliver negligible active hydrogen by the time of consumption.